See more : Wintrust Financial Corporation (WTFCM) Income Statement Analysis – Financial Results
Complete financial analysis of Genix Pharmaceuticals Corporation (GENPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genix Pharmaceuticals Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Phoenix Copper Limited (PXCLF) Income Statement Analysis – Financial Results
- Japan Exchange Group, Inc. (8697.T) Income Statement Analysis – Financial Results
- CoBank, ACB (CBKPP) Income Statement Analysis – Financial Results
- Agro Tech Foods Limited (ATFL.BO) Income Statement Analysis – Financial Results
- Newtek Business Services Corp. (NEWTL) Income Statement Analysis – Financial Results
Genix Pharmaceuticals Corporation (GENPF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.genixpharm.com
About Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and drops. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.35K | 0.00 | 0.00 | 0.00 | 137.40K | 419.96K | 1.01M | 924.70K | 650.86K | 373.13K | 595.00K | 603.11K | 573.28K | 282.80K | 407.27K | 223.18K | 200.51K | 818.26K | 1.31M | 1.23M | 1.30M | 809.91K | 904.53K | 1.34M | 2.60M | 3.10M |
| Cost of Revenue | 9.08K | 564.17K | 536.61K | 361.57K | 183.09K | 327.25K | 511.31K | 513.36K | 487.18K | 312.55K | 508.92K | 563.34K | 463.59K | 213.44K | 328.26K | 148.33K | 167.62K | 773.16K | 896.77K | 929.35K | 949.87K | 445.95K | 522.66K | 682.58K | 1.50M | 1.70M |
| Gross Profit | 3.26K | -564.17K | -536.61K | -361.57K | -45.69K | 92.72K | 499.20K | 411.34K | 163.68K | 60.59K | 86.08K | 39.77K | 109.69K | 69.37K | 79.00K | 74.85K | 32.90K | 45.10K | 412.54K | 298.94K | 348.51K | 363.96K | 381.88K | 655.95K | 1.10M | 1.40M |
| Gross Profit Ratio | 26.43% | 0.00% | 0.00% | 0.00% | -33.25% | 22.08% | 49.40% | 44.48% | 25.15% | 16.24% | 14.47% | 6.59% | 19.13% | 24.53% | 19.40% | 33.54% | 16.41% | 5.51% | 31.51% | 24.34% | 26.84% | 44.94% | 42.22% | 49.01% | 42.31% | 45.16% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 274.03K | 432.33K | 1.12M | 353.64K | 97.39K | 117.55K | 714.76K | 489.16K | 640.81K | 230.43K | 112.33K | 185.26K | 95.44K | 199.09K | 122.63K | 99.31K | 184.76K | 284.40K | 280.55K | 268.98K | 292.60K | 431.59K | 617.05K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 4.80K | 1.93K | 0.00 | 0.00 | 0.00 | 0.00 | 8.39K | 0.00 | 772.00 | 356.00 | 310.00 | 842.00 | 302.00 | 494.00 | 936.00 | 1.30K | 3.02K | 8.91K | 6.12K | 27.49K | 26.37K | 11.38K | 49.52K | 0.00 | 0.00 | 0.00 |
| SG&A | 278.83K | 434.26K | 1.12M | 353.64K | 97.39K | 117.55K | 723.15K | 489.16K | 641.58K | 230.79K | 112.64K | 186.10K | 95.74K | 199.59K | 123.56K | 100.60K | 187.77K | 293.31K | 286.67K | 296.46K | 318.98K | 442.97K | 666.57K | 729.25K | 1.60M | 1.30M |
| Other Expenses | -275.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 773.00 | -753.00 | -3.73K | 23.03K | 0.00 | 1.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.26K | 1.03M | 1.65M | 715.21K | 97.65K | 117.66K | 764.95K | 534.74K | 690.54K | 231.08K | 113.06K | 186.70K | 95.94K | 213.20K | 128.43K | 106.86K | 195.92K | 246.67K | 320.99K | 335.08K | 356.14K | 521.87K | 744.51K | 948.78K | 1.80M | 1.50M |
| Cost & Expenses | 12.35K | 1.03M | 1.65M | 715.21K | 280.73K | 444.90K | 1.28M | 1.05M | 1.18M | 543.63K | 621.98K | 750.05K | 559.53K | 426.63K | 456.69K | 255.20K | 363.53K | 1.02M | 1.22M | 1.26M | 1.31M | 967.82K | 1.27M | 1.63M | 3.30M | 3.20M |
| Interest Income | 354.00 | 148.00 | 1.45K | 432.00 | 0.00 | 0.00 | 128.00 | 512.00 | 2.18K | 2.87K | 0.00 | 314.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 52.28K | 12.13K | 3.51K | 3.88K | 1.78K | 826.00 | 16.61K | 16.22K | 1.27K | 1.84K | 1.35K | 9.38K | 16.64K | 14.77K | 15.76K | 15.08K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 547.42K | 564.17K | 536.61K | 361.57K | 253.00 | 109.00 | 155.00 | 45.61K | 48.96K | 295.00 | 421.00 | 601.00 | 195.00 | 251.00 | 4.87K | 6.26K | 8.14K | 19.47K | 35.57K | 44.22K | 44.43K | 153.44K | 208.17K | 219.53K | 200.00K | 200.00K |
| EBITDA | -3.80M | -466.90K | -1.12M | -317.68K | -143.08K | -23.94K | -57.37K | -83.22K | -495.75K | 26.10K | -205.04K | -146.02K | 14.72K | -143.58K | -44.56K | -25.76K | -154.88K | -248.22K | 127.12K | 8.08K | 36.80K | -4.47K | -154.46K | -73.29K | -500.00K | 100.00K |
| EBITDA Ratio | -30,753.83% | 0.00% | 0.00% | 0.00% | -104.14% | -5.91% | -22.15% | -8.36% | -73.14% | -45.61% | -4.46% | -24.21% | 2.43% | -50.07% | -10.94% | -11.54% | -77.24% | -13.86% | 9.71% | 0.66% | 2.83% | -0.55% | -17.08% | -5.48% | -19.23% | 3.23% |
| Operating Income | -880.89K | -1.03M | -1.65M | -715.67K | -143.34K | -26.13K | -282.37K | -139.62K | -528.46K | -172.34K | -28.33K | -146.94K | -2.89K | -158.60K | -65.19K | -47.09K | -163.02K | -270.25K | 91.55K | -36.14K | -7.63K | -157.91K | -362.63K | -292.83K | -700.00K | -100.00K |
| Operating Income Ratio | -7,134.48% | 0.00% | 0.00% | 0.00% | -104.32% | -6.22% | -27.94% | -15.10% | -81.19% | -46.19% | -4.76% | -24.36% | -0.50% | -56.08% | -16.01% | -21.10% | -81.30% | -33.03% | 6.99% | -2.94% | -0.59% | -19.50% | -40.09% | -21.88% | -26.92% | -3.23% |
| Total Other Income/Expenses | -3.51M | -42.93K | -578.76K | -2.99K | -21.37K | -1.26K | 27.11K | -35.26K | -17.52K | 5.57K | -165.05K | 58.97K | -15.87K | -2.72K | -3.73K | 23.03K | -5.49K | -66.80K | -19.83K | -11.78K | -35.74K | -3.04K | 1.15K | -7.44K | 0.00 | 0.00 |
| Income Before Tax | -4.40M | -1.07M | -1.65M | -718.66K | -164.70K | -24.84K | -243.21K | -129.05K | -545.98K | 31.67K | -193.37K | -87.97K | -2.11K | -161.32K | -68.93K | -24.06K | -168.51K | -337.05K | 71.72K | -47.93K | -43.37K | -160.95K | -361.48K | -300.26K | 0.00 | 0.00 |
| Income Before Tax Ratio | -35,600.34% | 0.00% | 0.00% | 0.00% | -119.87% | -5.92% | -24.07% | -13.96% | -83.89% | 8.49% | -32.50% | -14.59% | -0.37% | -57.04% | -16.92% | -10.78% | -84.04% | -41.19% | 5.48% | -3.90% | -3.34% | -19.87% | -39.96% | -22.43% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 12.13K | 3.51K | 3.88K | 1.78K | -158.09K | 16.61K | 16.22K | 1.27K | 1.84K | 1.35K | 9.38K | 16.64K | 15.39K | 15.76K | 15.08K | 15.39K | 152.16K | 0.00 | 0.00 | 0.00 | 101.31K | 141.31K | 14.16K | 100.00K | 0.00 |
| Net Income | -4.40M | -1.07M | -1.65M | -718.66K | -164.70K | 134.07K | -243.21K | -129.05K | -545.98K | 31.67K | -193.37K | -87.97K | -2.11K | -159.97K | -68.93K | -24.06K | -183.90K | -351.86K | 71.72K | -47.93K | -43.37K | -262.26K | -502.80K | -314.42K | -800.00K | -100.00K |
| Net Income Ratio | -35,600.34% | 0.00% | 0.00% | 0.00% | -119.87% | 31.92% | -24.07% | -13.96% | -83.89% | 8.49% | -32.50% | -14.59% | -0.37% | -56.57% | -16.92% | -10.78% | -91.71% | -43.00% | 5.48% | -3.90% | -3.34% | -32.38% | -55.59% | -23.49% | -30.77% | -3.23% |
| EPS | -0.07 | -0.02 | -0.03 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | -0.01 | -0.02 | 0.00 | 0.00 | 0.00 | -0.01 | -0.03 | -0.02 | -0.05 | -0.01 |
| EPS Diluted | -0.07 | -0.02 | -0.03 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | -0.01 | -0.02 | 0.00 | 0.00 | 0.00 | -0.01 | -0.03 | -0.02 | -0.05 | -0.01 |
| Weighted Avg Shares Out | 59.22M | 59.22M | 59.22M | 49.96M | 37.51M | 37.51M | 37.51M | 37.51M | 34.82M | 31.51M | 31.51M | 26.68M | 21.51M | 21.51M | 21.51M | 21.51M | 18.89M | 18.89M | 18.89M | 18.89M | 18.89M | 18.89M | 17.89M | 16.39M | 16.00M | 10.00M |
| Weighted Avg Shares Out (Dil) | 59.22M | 59.22M | 59.22M | 49.96M | 37.51M | 37.51M | 37.51M | 37.51M | 34.82M | 31.51M | 31.51M | 26.68M | 21.51M | 21.51M | 21.51M | 21.51M | 18.89M | 18.89M | 18.89M | 18.89M | 18.89M | 18.89M | 17.89M | 16.39M | 16.00M | 10.00M |
Genix Announces TSX-V Approval of Warrant Amendments
Genix Announces Warrant Repricing and Seeks Extension
Source: https://incomestatements.info
Category: Stock Reports